Kura Oncology (KURA) Competitors $7.90 -0.17 (-2.11%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$8.03 +0.13 (+1.59%) As of 08/29/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock KURA vs. GMTX, CPRX, ALVO, KNSA, OGN, TARS, CNTA, DNLI, AGIO, and IDYAShould you be buying Kura Oncology stock or one of its competitors? The main competitors of Kura Oncology include Gemini Therapeutics (GMTX), Catalyst Pharmaceuticals (CPRX), Alvotech (ALVO), Kiniksa Pharmaceuticals International (KNSA), Organon & Co. (OGN), Tarsus Pharmaceuticals (TARS), Centessa Pharmaceuticals (CNTA), Denali Therapeutics (DNLI), Agios Pharmaceuticals (AGIO), and IDEAYA Biosciences (IDYA). These companies are all part of the "pharmaceutical products" industry. Kura Oncology vs. Its Competitors Gemini Therapeutics Catalyst Pharmaceuticals Alvotech Kiniksa Pharmaceuticals International Organon & Co. Tarsus Pharmaceuticals Centessa Pharmaceuticals Denali Therapeutics Agios Pharmaceuticals IDEAYA Biosciences Gemini Therapeutics (NASDAQ:GMTX) and Kura Oncology (NASDAQ:KURA) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends. Do institutionals & insiders have more ownership in GMTX or KURA? 75.4% of Gemini Therapeutics shares are owned by institutional investors. 12.9% of Gemini Therapeutics shares are owned by insiders. Comparatively, 6.4% of Kura Oncology shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is GMTX or KURA more profitable? Gemini Therapeutics' return on equity of -38.78% beat Kura Oncology's return on equity.Company Net Margins Return on Equity Return on Assets Gemini TherapeuticsN/A -38.78% -35.88% Kura Oncology N/A -52.32%-29.59% Which has stronger earnings & valuation, GMTX or KURA? Gemini Therapeutics has higher earnings, but lower revenue than Kura Oncology. Gemini Therapeutics is trading at a lower price-to-earnings ratio than Kura Oncology, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGemini TherapeuticsN/AN/A-$71.87M-$1.00-59.65Kura Oncology$53.88M12.73-$173.98M-$2.26-3.50 Do analysts rate GMTX or KURA? Kura Oncology has a consensus target price of $24.10, suggesting a potential upside of 205.06%. Given Kura Oncology's stronger consensus rating and higher possible upside, analysts plainly believe Kura Oncology is more favorable than Gemini Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Gemini Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Kura Oncology 0 Sell rating(s) 3 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 2.86 Which has more volatility and risk, GMTX or KURA? Gemini Therapeutics has a beta of -0.12, indicating that its share price is 112% less volatile than the S&P 500. Comparatively, Kura Oncology has a beta of 0.41, indicating that its share price is 59% less volatile than the S&P 500. Does the media favor GMTX or KURA? In the previous week, Kura Oncology had 5 more articles in the media than Gemini Therapeutics. MarketBeat recorded 6 mentions for Kura Oncology and 1 mentions for Gemini Therapeutics. Kura Oncology's average media sentiment score of 1.51 beat Gemini Therapeutics' score of 0.75 indicating that Kura Oncology is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Gemini Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Kura Oncology 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive SummaryKura Oncology beats Gemini Therapeutics on 10 of the 15 factors compared between the two stocks. Get Kura Oncology News Delivered to You Automatically Sign up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding KURA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart KURA vs. The Competition Export to ExcelMetricKura OncologyMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$685.70M$3.08B$5.75B$9.77BDividend YieldN/A2.28%4.10%4.04%P/E Ratio-3.5020.7883.2726.59Price / Sales12.73374.32530.10108.40Price / CashN/A44.2237.4459.26Price / Book2.248.0710.556.58Net Income-$173.98M-$53.98M$3.27B$265.95M7 Day Performance3.27%-0.88%0.40%0.17%1 Month Performance30.58%7.72%7.31%3.90%1 Year Performance-62.49%7.03%46.58%19.67% Kura Oncology Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)KURAKura Oncology3.9344 of 5 stars$7.90-2.1%$24.10+205.1%-62.5%$685.70M$53.88M-3.50130News CoveragePositive NewsGMTXGemini TherapeuticsN/A$60.35+1.0%N/A+22.2%$2.61BN/A-60.3530News CoverageCPRXCatalyst Pharmaceuticals4.8224 of 5 stars$20.62-2.2%$33.20+61.0%+1.7%$2.58B$491.73M12.5080News CoveragePositive NewsInsider TradeGap UpALVOAlvotech2.9312 of 5 stars$8.32-1.5%$14.00+68.3%-30.9%$2.55B$491.98M36.171,032Gap UpKNSAKiniksa Pharmaceuticals International2.053 of 5 stars$33.04-2.1%$41.17+24.6%+25.2%$2.50B$423.24M826.21220News CoveragePositive NewsAnalyst DowngradeOGNOrganon & Co.4.7607 of 5 stars$9.08-3.8%$18.00+98.3%-58.0%$2.45B$6.40B3.374,000Positive NewsTARSTarsus Pharmaceuticals1.6902 of 5 stars$56.61-1.1%$66.67+17.8%+116.1%$2.42B$182.95M-24.3050News CoveragePositive NewsCNTACentessa Pharmaceuticals2.6174 of 5 stars$17.00-0.1%$28.10+65.3%+24.4%$2.28B$6.85M-9.50200News CoverageAnalyst ForecastDNLIDenali Therapeutics4.1759 of 5 stars$15.57+0.5%$33.62+115.9%-37.5%$2.26B$330.53M-5.56430News CoveragePositive NewsAGIOAgios Pharmaceuticals4.3521 of 5 stars$37.26-4.0%$56.33+51.2%-17.9%$2.25B$36.50M3.39390News CoveragePositive NewsIDYAIDEAYA Biosciences4.4205 of 5 stars$24.71-1.6%$48.09+94.6%-37.8%$2.20B$7M-6.5280News CoveragePositive News Related Companies and Tools Related Companies GMTX Alternatives CPRX Alternatives ALVO Alternatives KNSA Alternatives OGN Alternatives TARS Alternatives CNTA Alternatives DNLI Alternatives AGIO Alternatives IDYA Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:KURA) was last updated on 8/31/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kura Oncology, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Kura Oncology With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free KURA Stock Alerts